2016
Transient P2X7 Receptor Antagonism Produces Lasting Reductions in Spontaneous Seizures and Gliosis in Experimental Temporal Lobe EpilepsyJimenez-Pacheco A, Diaz-Hernandez M, Arribas-Blazquez M, Sanz-Rodriguez A, Olivos-Ore L A, Artalejo A R, Alves M, Letavic M, Miras-Portugal M T, Conroy R M, Delanty N, Farrell M A, O'Brien D F, Bhattacharya A, Engel T, Henshall D C. J Neurosci. 2016; 36 (22): 5920-5932. doi: 10.1523/JNEUROSCI.4009-15.2016
Design and synthesis of DNA-encoded libraries based on a benzodiazepine and a pyrazolopyrimidine scaffoldŠkopić M K, Bugain O, Jung K, Onstein S, Brandherm S, Kalliokoski T, Brunschweiger A. MedChemComm. 2016; 7 (10): 1957-1965. doi: 10.1039/c6md00243a
Characterization of RON protein isoforms in pancreatic cancer: implications for biology and therapeuticsChakedis J, French R, Babicky M, Jaquish D, Mose E, Cheng P, Holman P, Howard H, Miyamoto J, Porras P, Walterscheid Z, Schultz-Fademrecht C, Esdar C, Schadt O, Eickhoff J, Lowy A M. Oncotarget. 2016; 7 (29): 45959-45975. doi: 10.18632/oncotarget.10009
Critical Evaluation of P2X7 Receptor Antagonists in Selected Seizure ModelsFischer W, Franke H, Krugel U, Muller H, Dinkel K, Lord B, Letavic M A, Henshall D C, Engel T. PLoS One. 2016; 11 (6): e0156468. doi: 10.1371/journal.pone.0156468
Identification of pyrazolopyridazinones as PDEδ inhibitorsPapke B, Murarka S, Vogel H A, Martin-Gago P, Kovacevic M, Truxius D C, Fansa E K, Ismail S, Zimmermann G, Heinelt K, Schultz-Fademrecht C, Al Saabi A, Baumann M, Nussbaumer P, Wittinghofer A, Waldmann H, Bastiaens P I. Nat Commun. 2016; 7 11360. doi: 10.1038/ncomms11360
The Evolving Role of the Medicinal ChemistLawton G, Nussbaumer P. Prog Med Chem. 2016; 55 193-226. doi: 10.1016/bs.pmch.2015.11.001